Paradigm Shift

Repurposing

Paradigm Biopharmaceuticals is a commercially focussed drug repurposing company. We take an existing approved drug, which has demonstrated safety in its approved indication/s and repurpose that drug in a new, patented therapeutic application addressing areas of high unmet medical need. With our extensive understanding of the scientific, clinical, regulatory, and commercial requirements of drug development, we can achieve a reduction in the time, cost and risk associated with taking new products to market.
READ MOREREAD MORE

Science from a different angle

Without doubt, some of medicine’s greatest opportunities have never come to light because they were consigned to the darkened corners of history before we had the technology or techniques to fully investigate them. Combining cutting edge science and unparalleled experience, Paradigm Biopharma is uniquely qualified to identify and liberate the true potential of under-utilised drugs and molecules to meet some of the world’s most significant unmet needs

READ MOREREAD MORE

Experts in uncovering the real value of a molecule

Our focus

Pentosan Polysulphate Sodium (PPS)

Paradigm’s immediate commercial focus is the repurposing of Pentosan Polysulphate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.

READ MOREREAD MORE

Inflammation

In the presence of inflammation, the body can’t begin regenerating. We are targeting Osteoarthritis (OA) and other conditions with Pentosan Polysulphate Sodium (PPS) because it may address the complex biological responses to injury, infection, or allergy which have short and long-term components mediated by factors produced by immune cells.

READ MOREREAD MORE

Recent Highlights

Click here for all ASX announcements.

Paradigm Biopharmaceuticals to Present at the 7th Annual Truist Securities Life Sciences Summit.

3rd May 2021

The conference is being held virtually on May 4-5 (US) with Paradigm participating in a 40-minute fireside chat with a Truist healthcare analyst. During the event, members of the Paradigm executive leadership will engage in 1×1 investor meetings.

READ MOREREAD MORE

Paradigm Biopharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

6th January 2021

Paradigm’s management will also be participating in several meetings throughout the conference with pharmaceutical companies and specialist US Biotech and Healthcare funds, where the company will be detailing its Phase 3 clinical program for Zilosul® and discussing other exciting indications in the company’s clinical pipeline.
READ MOREREAD MORE

Paradigm hosts 1st Inaugural R&D Day

21st Decemeber 2020

Paradigm’s R&D presentation provides a detailed explanation of the clinical trial program required to achieve successful global registration for OA which is based on feedback received from the Scientific Advice meeting with the EMA in September and the Type-C meeting with the US FDA.
READ MOREREAD MORE

There a pipeline of potential indications for the use of PPS

POTENTIAL INDICATIONS

Alphavirus

Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.

*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016

Osteoarthritis (OA)

OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.

*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September

Mucopolysaccharidosis (MPS)

Mucopolysaccharidoses are lysosomal storage disorders characterised by accumulation of abnormal pathological glycosaminoglycans, cellular dysfunction and widespread inflammation, resulting in progressive cognitive and motor decline.

Chronic Heart Failure (CHF)

Occurs in about 1% of people aged 50-59, but becomes more common from 80+ where its occurrence rate is over 50%. Lifetime risk for developing heart failure is 1 in 5 among both men and women.

Research & Development

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.

READ MORE